Frontiers in Psychiatry
September 3, 2026
Anita Słupska, Wiesław Jerzy Cubała, Damian Swieczkowski et al.
Objectives Ketamine and esketamine are increasingly used for treatment-resistant depressive disorders, particularly when rapid symptom reduction is clinically desirable. Intranasal esketamine has a product-specific regulatory framework in several jurisdictions, whereas most racemic ketamine formulations remain off-label for psychiatric indications. This narrative review provides practical...
Frontiers in Psychiatry
September 3, 2026
Mary R. Shen, Kwadwo Owusu-Boaitey, Zackari D. Murphy et al.
IntroductionOpioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone. Persistent challenges with treatment retention, access, stigma, and incomplete response highlight the need for adjunctive pharmacotherapies targeting neurobiological systems beyond the mu-opioid receptor.MethodsWe conducted a...
Frontiers in Psychiatry
September 1, 2026
Gabrielle Agin-Liebes, Sarah Shnayder, Geena Fram et al.
Introduction Psilocybin treatment has shown promise for treatment-resistant obsessive-compulsive disorder (OCD), yet clinical response is variable. Little is known about the subjective experiences associated with divergent outcomes or the psychological processes differentiating responders from non-responders. Materials and methods A qualitative case comparison was conducted using...
Frontiers in Psychiatry
August 26, 2026
Jon Berner
Background Multiple preclinical and clinical reports suggest that rapamycin augmentation may increase the safety and efficacy of ketamine treatment. Population variability in patient biochemical gain-of-function and phenotypic admixtures, however, has slowed initial investigations into patient selection and dose finding. Methods A single-center, retrospective chart review identified 101...
Frontiers in Psychiatry
August 19, 2026
Alan Maddock, Thearith Heang, Nil Ean et al.
Objectives Mindfulness is increasingly used in global mental health, yet its measurement tools are largely developed within Western cultural frameworks. This study aimed to (1) translate and culturally adapt the Southampton Mindfulness Questionnaire (SMQ) into Khmer, (2) evaluate its cultural integrity among Cambodian adults with physical disabilities, and (3) examine the psychometric...
Frontiers in Psychiatry
August 19, 2026
Jeni Page, Alexandra Moore, Bridget E. Hawkins et al.
IntroductionMicrodosing psilocybin magic mushrooms (MM) and truffles has grown in popularity, but the evidence supporting reported benefits remains poorly characterized. The purpose of this systematic review was to synthesize the existing literature on microdosing psilocybin MM and truffles in adults to determine reported health effects and perceived benefits, motivations for use, dosing...
Frontiers in Psychiatry
August 17, 2026
Balázs Barko, Szabolcs Kéri
Introduction: Neuronal mechanisms of motion perception are susceptible to developmental anomalies. We tested whether heavy adolescent cannabis use is associated with enduring deficits in global motion perception, with relative sparing of global form perception, in abstinent adults. Methods: In a cross-sectional study, 130 adults were enrolled: cannabis-naïve controls (n=50), non-heavy...
Frontiers in Psychiatry
August 12, 2026
Anthony L. Back, Robert Bosnak
Psilocybin therapy in patients with cancer commonly produces vivid embodied and imaginal experiences that resist verbal description, yet most current integration approaches rely primarily on cognitive and verbal processing. We hypothesize that an approach to integration that directly engages this embodied register, without requiring translation into a verbal narrative, will enable patients to...
Frontiers in Psychiatry
August 11, 2026
Ngo Cheung
Quantum approaches to consciousness remain controversial, partly because any putative quantum state in the brain is expected to decohere rapidly in a warm, hydrated, and noisy environment. The present manuscript does not attempt to solve that biological problem directly. Instead, it treats microtubule-related interpretation as a deliberately hypothetical analogy and asks a narrower Level-A...
Frontiers in Psychiatry
August 10, 2026
D. Beasley
Prior work in computational psychiatry has identified three failure modes of precision weighting that produce the phenomenology of individual-level psychosis: aberrant precision on priors, aberrant precision on sensory likelihood, and aberrant meta-precision. The coupled, dyadic case has remained outside this framework. We identify a fourth failure mode, dyadic precision migration, in which...
Frontiers in Psychiatry
August 6, 2026
Maria Laura Mele, Stefano Federici
IntroductionPsychedelic-assisted therapy (PAT) is an emerging complex intervention for psychiatric and existential conditions (i.e., forms of distress related to meaning, mortality, and identity, such as that arising in life-threatening illness); however, a systematic characterization of the evaluation methods used across the entire clinical intervention remains incomplete. This scoping review...
Frontiers in Psychiatry
August 5, 2026
Zhi-Wen Gu, Xin Qin, Chang-Ping Yang et al.
Background Clinical nurses are essential to healthcare, but they experience high rates of depression, anxiety, and sleep disturbances. This study examined the relationships among occupational stressors, sleep problems, mindfulness, and psychological well-being in hospital nurses. Methods In a cross-sectional study of 416 clinical nurses from a tertiary general hospital in China, we assessed...
Frontiers in Psychiatry
August 4, 2026
Gaoqin Tang, Unfai Cho, Jun Zhang et al.
Background: Perinatal depression is a highly common clinical complication. While expert panels advocate for non-pharmacological treatments, the relative benefits of mindfulness-based interventions delivered face-to-face versus through emerging digital platforms have not been examined within a single integrated synthesis that distinguishes the contribution of delivery mode from that of trial era...
Frontiers in Psychiatry
July 30, 2026
Liangju Chen, Yonghua Chen, Ying Zhao et al.
Objectives: This article reviews the clinical status and treatment challenges of cancer-related depressive states, clarifies the mechanism of action of esketamine-a novel rapid-acting antidepressant-compares its efficacy with traditional drugs, evaluates safety and tolerability, and summarizes clinical evidence to support clinical practice and research. Methods: By searching databases such as...
Frontiers in Psychiatry
July 30, 2026
Muhammad Abbas, Bruno Kallas, Max Garris
This is a case report of a 52 year old female with ECT-refractory bipolar depression who was treated with esketamine nasal spray, leading to a noticeable improvement in her depressive symptoms. She experienced a relapse after a reduction in her maintenance treatment in conjunction with psychosocial stressors, but improved once again after returning to her induction regimen. She tolerated the...
Frontiers in Psychiatry
July 29, 2026
Caitlyn Hanna Sams, Jasmine Davis, Anuradha Ramdas et al.
We report two case studies that examine the therapeutic potential of structured psilocybin-containing mushroom biomass regimens administered within a clinical framework, evaluating their impact on mental health outcomes as well as associated somatic symptoms. Two patients underwent the De La Haye Psilocybin Treatment Protocol (DPTP), which integrates micro- and high-doses (combined psilocybin...
Frontiers in Psychiatry
July 28, 2026
Chenghan Zhang, Hao Huang, Guotao Wu et al.
Background and objective: Within the interdisciplinary field of cyberpsychology and mental health, trait mindfulness has been associated with lower levels of subclinical anomalous symptoms, such as Psychotic-Like Experiences (PLEs), has gained increasing attention. However, in the context of daily digital human-computer interactions (e.g., listening to AI-generated music), the specific pathways...
Frontiers in Psychiatry
July 21, 2026
David Martinez Garza, Ilya O. Blokhin, Jonathan Brett et al.
Since the introduction of disulfiram in 1951 (the first ever Food and Drug Administration (FDA)-approved medication for substance use disorders (SUDs)) (1), only seven other individual medications have been approved for the treatment of SUDs. While the repurpose of medications and different formulations increase the total number of FDA-approved medicines (Table 1 and(2)), the arsenal of...
Frontiers in Psychiatry
July 21, 2026
Kenneth P. Finn, Robin Murray, Elizabeth Stuyt et al.
Cannabis is one of the most widely used psychoactive substances, with higher use rates in countries that have implemented policies to legalize medical or recreational use. Following the development of cannabis products with concentrations well above 10% THC (high potency, delta-9 tetrahydrocannabinol), the number of psychosis cases has also increased. Cannabis-attributable psychosis cases...
Frontiers in Psychiatry
July 20, 2026
Sergio Pérez Rosal, Sonya C. Faber, Markus Backmund
Substance use disorders (SUD) involving ketamine, cocaine, and alcohol present significant clinical challenges, often characterized by high relapse rates and limited pharmacological options. This case report details a 30-year-old male with a five-year history of severe polysubstance dependence, including daily intranasal ketamine use (2–3 g/day), cocaine, and alcohol, comorbid with recurrent...
Frontiers in Psychiatry
July 20, 2026
Bruce Tamilson, Michael Chitolie, Jan Coebergh et al.
Background and aimFunctional neurological disorder (FND) is a common and disabling condition for which effective treatments remain limited. Clinical outcomes are often variable, particularly in chronic and comorbid presentations. Ketamine and esketamine are increasingly used across a range of neuropsychiatric conditions. This review aimed to synthesise the existing evidence regarding their use...
Frontiers in Psychiatry
July 17, 2026
Shu-Ping Fang, Xin Yang, Da-Cong Zhao et al.
Introduction Substance use disorder (SUD) is a major global health issue, contributing significantly to the disease burden. Despite this, effective treatments for SUD remain limited. Ketamine has shown potential as a treatment, yet no meta-analysis has assessed its efficacy for SUD. This study aimed to evaluate the efficacy and safety of ketamine in treating SUD. Methods Multiple databases were...
Frontiers in Psychiatry
July 16, 2026
Giovanna Azevedo Rodrigues, Fernando Martins Castanheira, Larissa Leite Vieira de Oliveira et al.
Categorical nosological systems frequently fall short when confronted with patients whose presentations cross established diagnostic boundaries. We report M.S., a 44-year-old Brazilian man involuntarily admitted to a psychiatric inpatient unit who presented with systematized persecutory ideation of mechanistic–technological content (chip implantation, satellite-based surveillance), structural...
Frontiers in Psychiatry
July 15, 2026
Rafał Marecki, Wiktoria Zaniewska, Adam Hamed et al.
Classic psychedelics, including psilocybin, LSD, DMT, 5-MeO-DMT, mescaline, and phenethylamines such as DOI, exert their core effects through 5-HT2A receptor agonism, inducing widespread neurobiological and behavioral changes relevant to psychiatric research. Emerging evidence suggests that these effects are modulated by sex, yet this dimension remains underrepresented in studies. This review...
Frontiers in Psychiatry
July 13, 2026
Scott Shannon, Andrew T. Weil
Current psychiatric models, while clinically valuable, remain limited in their ability to account for the complexity, variability, and context dependence of mental disorders. Converging evidence from neuroscience, complexity science, and psychedelic research suggests that psychiatric symptoms may be better understood as stable patterns of organization within dynamic, multilevel systems rather...